



PATENT
Docket No. 255.00040101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sheridan et al.)
Serial No.: 09/727,739)
Confirmation No.: 4181)
Filed: December 1, 2000)
For: SOMATOSTATINS AND METHODS

Group Art Unit: 1646

Examiner: R. Li

RECEIVED 6/6/02
18/D
JUN 05 2002

TECH CENTER 1600/2900

**COMMUNICATION RE: NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

This is in response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures," mailed April 30, 2002, concerning errors in the previously submitted computer readable form (CRF) of the Sequence Listing. The Sequence Listing Error Report indicates that the intentionally skipped sequence (SEQ ID NO:35) was not properly formatted.

In accordance with 37 C.F.R. §1.821, submitted herewith please find a substitute computer readable form (CRF) copy and a paper copy of the Sequence Listing. Applicants request entry of same into the specification. For the intentionally skipped sequences, only fields <210> and <400> are utilized. Applicants state that the content of the sequence listing information recorded in computer readable form (CRF) is identical to the paper copy, and that the sequence listing does not contain new matter.

Please charge any additional fees or credit any over-payment to PTO Deposit Account No. 13-4895.

Communication

2 of 2


Applicant(s): Sheridan et al.

Serial No. 09/727,739

Filed: December 1, 2000

For: SOMATOSTATINS AND METHODS

The application should now be in condition for examination. Please direct any inquiries to the undersigned attorney.

CERTIFICATE UNDER 37 C.F.R. 1.8:
The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA, 22202, on this <u>24</u> day of <u>MAY</u> , 2002.  Victoria A. Sandberg

Respectfully submitted for

Sheridan et al.

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Facsimile (612)305-1228

Customer Number 26813




26813

PATENT TRADEMARK OFFICE

24 May 2002
Date

By:


Victoria A. Sandberg

Reg. No. 41,287

Direct Dial (612)305-1226

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823; as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: _____

RECEIVED

JUN 05 2002

Applicant Must Provide:

TECH CENTER 1600/2900

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-308-6900

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 29 2002

Applicant(s): Sheridan et al.

Group Art Unit: 1646

Serial No.: 09/727,739

Examiner: R. Li

Filed: December 1, 2000

Docket No.: 255.00040101

Title: SOMATOSTATINS AND METHODS

Confirmation No.: 4181

U.S. Patent and Trademark Office
 Box Sequence
 P.O. Box 2327
 Arlington, VA 22202

RECEIVED

JUN 05 2002

TECH CENTER 1600/2900

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

Small entity status is entitled to be asserted in the above-identified application.

An itemized return postcard.

A Petition for Extension of Time for ___ month(s) and a check in the amount of \$___ for the required fee.

An Information Disclosure Statement (___ pgs); copies of ___ applications; 1449 forms (___ pgs); and copies of ___ documents cited on the 1449 forms.

A check in the amount of \$___, representing ___.

Other: Communication Re: Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pgs); copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg); Sequence Listing (22 pgs); and Sequence Listing in Computer Readable Format (1 disk).

Amendment No Additional fee is required. The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$42 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$140 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on this 24 day of MAY, 2002.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813



26813

PATENT TRADEMARK OFFICE

By: Victoria A. Sandberg
 Name: Victoria A. Sandberg
 Reg. No.: 41,287
 Direct Dial: 612-305-1226
 Facsimile: 612-305-1228

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.8)

DATE: 6/5/02

DRAFT IN USE

1646